Keyword: Ionis Pharmaceuticals
The results wiped 50% off Wave’s share price, adding to losses it suffered when it dumped a Duchenne muscular dystrophy program earlier in December.
Looks like Biogen is going all in on Alzheimer’s disease—the Big Biotech is picking up a tau-targeting treatment from Ionis for $45 million upfront.
For $250 million up front, Akcea is licensing an antisense therapy to Pfizer, to be developed for “certain cardiovascular and metabolic diseases.”
A week after Sarah Boyce exited Akcea, she's at the helm of Avidity Biosciences, a company aiming to take antibody-drug conjugates to the next level.
Akcea CEO Paula Soteropoulos, President Sarah Boyce and Chief Operating Officer Jeff Goldberg are bidding the company adieu.
The deal comes shortly after GlaxoSmithKline achieved clinical proof of concept for the Ionis-partnered hepatitis B program.
ALS patients on the highest dose of Biogen's tofersen (BIIB067) showed a slowdown in the progression of symptoms in a phase 1 trial.
The decision sets Novartis up to test the RNA-targeting drug in a phase 3 cardiovascular outcomes trial.
Akcea and Ionis' self-administered Tegsedi is more convenient than Alnylam's Onpattro, but it comes with a boxed warning.
ProQR is licensing an RNA medicine from Ionis Pharmaceuticals for the treatment of retinitis pigmentosa, a form of rare, inherited blindness.